Better Therapeutics Appoints Thiago Licias de Oliveira as Its Chief People Officer
November 04 2021 - 8:00AM
Business Wire
Better Therapeutics, Inc. (“Better Therapeutics”; NASDAQ: BTTX),
a prescription digital therapeutics company delivering cognitive
behavioral therapy to address the root causes of cardiometabolic
diseases, today announced the appointment of Thiago Licias de
Oliveira as its Chief People Officer. In this newly created role,
Thiago will develop and implement a people strategy to build,
structure and retain an exceptional team through a period of
anticipated high growth. Most recently, Thiago was the Head of
Global Talent Management for Johnson & Johnson Medical
Devices.
“Thiago is a passionate leader who embraces the critical
importance of people in enabling companies to succeed,” said Kevin
Appelbaum, Co-founder and CEO of Better Therapeutics. “We look
forward to his leadership and creativity in furthering our ability
to attract, retain and develop uniquely capable talent as we
pioneer new ways to treat cardiometabolic diseases.”
“Innovation only happens when diverse, talented and passionate
people come together with common purpose and a mission focus,” said
de Oliveira. “My goal is to assemble and help unlock the potential
that lies within a diverse and driven organization to achieve our
greatest aspirations.”
De Oliveira received his MBA through ESADE Business School in
Barcelona, Spain, and New York University. He is also a certified
leadership coach who helps emerging market and social entrepreneurs
elevate their leadership capabilities.
About Better Therapeutics
Better Therapeutics is a prescription digital therapeutics (PDT)
company developing a novel form of cognitive behavioral therapy to
address the root causes of cardiometabolic diseases. The company
has developed a proprietary platform for the development of
FDA-regulated, software-based solutions for type 2 diabetes, heart
disease and other conditions. The cognitive behavioral therapy
delivered by Better Therapeutics’ PDT is designed to enable changes
in neural pathways of the brain so lasting changes in behavior
become possible. Addressing the underlying causes of these diseases
has the potential to dramatically improve patient health while
lowering healthcare costs. Better Therapeutics clinically validated
mobile applications are intended to be prescribed by physicians and
reimbursed like traditional medicines. For more information visit:
bettertx.com
Forward-Looking Statements
This press release contains “forward-looking statements” within
the meaning of the United States Private Securities Litigation
Reform Act of 1995. These forward-looking statements include, but
are not limited to, statements regarding the delivery of cognitive
behavioral therapy by Better Therapeutics to address the root
causes of type 2 diabetes and other cardiometabolic diseases;
development of a proprietary platform and software-based solutions
for treatment of type 2 diabetes, heart disease and other
conditions; achievement of changes in neural pathways of the brain
and lasting changes in behavior through cognitive behavioral
therapy delivered by Better Therapeutics’ PDT; the capability of
Better Therapeutics to address the underlying causes of certain
diseases and its related potential to improve patient health while
lowering healthcare costs; the potential for Better Therapeutics’
clinically validated mobile applications to be prescribed by
physicians and reimbursed like traditional medicines; potential and
significance of the results of the pivotal study of BT-001 or any
clinical or other trial; the potential success of BT-001 as a
prescribed treatment used under physician supervision for people
with uncontrolled type 2 diabetes; the possibility for the results
of the pivotal study to support a regulatory submission for
marketing authorization from the FDA; the potential timing of, and
Better Therapeutics’ expected progress towards developing and
obtaining FDA approval for its products, related research and
validation studies. In addition, any statements that refer to
projections (including EBITDA, adjusted EBITDA, EBITDA margin and
revenue projections), forecasts or other characterizations of
future events or circumstances, including any underlying
assumptions, are forward-looking statements. Forward-looking
statements are typically identified by words such as “plan,”
“believe,” “expect,” “anticipate,” “intend,” “outlook,” “estimate,”
“forecast,” “project,” “continue,” “could,” “may,” “might,”
“possible,” “potential,” “predict,” “should,” “would” and other
similar words and expressions, but the absence of these words does
not mean that a statement is not forward-looking. Any
forward-looking statements in this press release are based on
management’s current expectations of future events and are subject
to a number of risks and uncertainties that could cause actual
results to differ materially and adversely from those set forth in
or implied by such forward-looking statements. These risks and
uncertainties include, but are not limited to, the risk that the
FDA may not be satisfied with the design of any of Better
Therapeutics’ studies and trials, and even satisfied, payers may
not reimburse BT-001, if approved,, the risk that the results of
previously conducted studies will not be repeated or observed in
ongoing or future studies involving our product candidates, and the
risk that the current COVID-19 pandemic will impact Better
Therapeutics’ platform validation, product testing, the timing of
the Better Therapeutics’ submission of the BT-001 for marketing
approval from the FDA and other operations. For a discussion of
other risks and uncertainties, and other important factors, any of
which could cause Better Therapeutics' actual results to differ
from those contained in the forward-looking statements, see the
section entitled “Risk Factors” in Mountain Crest II’s filings on
file with the Securities and Exchange Commission, available at the
Securities and Exchange Commission’s website at www.sec.gov, and as
well as discussions of potential risks, uncertainties and other
important factors in Mountain Crest II and/or Better Therapeutics’
subsequent/future filings, if any, with the Securities and Exchange
Commission. All information in this press release is as of the date
of the release, and the Company undertakes no duty to update this
information unless required by law.
BTTX-PR
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211104005474/en/
Media Contact Heidi Chokeir, Ph.D.
heidi.chokeir@canalecomm.com +1 619 203 5391
Better Therapeutics (NASDAQ:BTTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Better Therapeutics (NASDAQ:BTTX)
Historical Stock Chart
From Apr 2023 to Apr 2024